Pharma BD Deal Intelligence
Ception Therapeutics never got to prove itself under Cephalon—the buyer was swallowed by Teva 18 months later, and Teva carried reslizumab (Cinqair) to a 2016 approval as an IV-only also-ran that lost the convenience war to GSK's Nucala and AstraZeneca's Fasenra. A subcutaneous fix failed Phase III in 2018, and the drug never appeared as a named revenue line in Teva's filings.
Cephalon executes biologics diversification thesis with $250M Ception buyout following positive reslizumab Phase 2 in eosinophilic asthma.
Cephalon announced completion of the Ception acquisition, with Ception becoming a wholly-owned subsidiary and Cephalon purchasing all outstanding capital stock…
Reslizumab journey from Schering-Plough → Ception → Cephalon ($250M, 2010) → Teva ($6.8B, 2011) → FDA approval as Cinqair in March 2016 for severe eosinophilic…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Cephalon exercised option to acquire Ception for $250M following positive Phase 2 eosinophilic asthma data on reslizumab.
Assessment window: 10yr post-close.
$3.2B Global eosinophilic asthma market 2025
Severe eosinophilic asthma is a phenotype of asthma characterized by elevated blood and airway eosinophils driving Th2-mediated inflammation that resists standard inhaled corticosteroids. Patients suffer frequent exacerbations, oral steroid dependence, and impaired lung function. The IL-5 pathway is the central driver of eosinophil maturation and trafficking, making it the validated therapeutic target.
In 2010 when Cephalon acquired Ception for $250M, the severe eosinophilic asthma biologics class was nascent — no anti-IL-5 therapy was yet approved. Reslizumab competed conceptually with GSK's mepolizumab (Nucala), then in late-stage development, and AstraZeneca's tralokinumab/benralizumab programs. Existing severe-asthma options were limited to Genentech/Novartis's omalizumab (Xolair, anti-IgE, 2003 approval) for allergic asthma plus oral corticosteroids. The acquisition validated Cephalon's biologics diversification strategy — reslizumab Phase 2 data in 106 patients showed FEV1 improvement (p=0.002) and sputum eosinophil reduction (p=0.006). Teva acquired Cephalon for $6.8B in 2011, inheriting the program; Cinqair (reslizumab) ultimately won FDA approval in March 2016. Commercially, reslizumab struggled — IV-only administration disadvantaged it versus GSK's subcutaneous Nucala (approved Nov 2015) and AZ's Fasenra (benralizumab, 2017). The class moved on to Sanofi/Regeneron's Dupixent (dupilumab, anti-IL-4Rα), which now dominates Type-2 inflammation. The 2010 deal logic was sound; commercial outcome was modest.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cephalon Inc. / Ception Therapeutics (this deal) | 2010 | $250M | 23 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
| Cephalon Inc. / Cell Therapeutics, Inc. | 2005 | $70M | 74 |
| Cephalon Inc. / Anesta Corp. | 2001 | $444M | 65 |
| Cephalon Inc. / Anesta Corp. | 2000 | $444M | 64 |
← Browse all deals · How we score deals
More: 2010 deals · Cephalon Inc. deals · Respiratory deals